How Does Green Cross Company Work?

Green Cross company's operations revolve around creating essential protein therapies and vaccines. Their work targets critical health areas, aiming to improve patient outcomes globally.

The company's value proposition is built on delivering innovative and accessible healthcare solutions. They strive to enhance global health by providing vital treatments for various medical conditions.

A robust manufacturing infrastructure supports Green Cross company's operations, including facilities for plasma testing, protein separation, virus inactivation, and aseptic filling. This ensures the quality and safety of their products.

Green Cross company maintains extensive supply chain and distribution networks, supplying pharmaceutical products to approximately 40 countries worldwide. Key partnerships with major U.S. pharmacy benefit management companies and specialty pharmacies are crucial for broad product distribution.

A significant recent milestone for Green Cross company operations was the U.S. FDA approval of its immunoglobulin blood product, Alyglo, in December 2023. This paved the way for its U.S. launch in July 2024, with initial shipments reaching patients by mid-July. In 2025, the company also secured MFDS approval for the world's first recombinant anthrax vaccine.

The company has actively prepared for its U.S. launch by securing partnerships with major U.S. Pharmacy Benefit Managers (PBMs) and specialty pharmacies, ensuring broad distribution. In November 2024, Green Cross, in collaboration with Novel Pharma, dosed the first patient in a multinational Phase I clinical trial for GC1130A, an innovative new drug for Sanfillippo syndrome type A.

Despite facing challenges such as a slight decline in domestic prescription drug revenue in Q3 2024 due to a doctors' strike, Green Cross company operations have adapted. The company focused on overseas sales, evidenced by the recovery of Hunterase exports to Russia, and increased supply volume for the National Immunization Program for vaccines.

Green Cross's competitive advantages include its brand strength, over half a century of experience, and expertise in plasma-derived products and vaccines. The company's commitment to rare disease treatments and investment in R&D for innovative drugs and mRNA platforms further differentiate its Green Cross business model.

GC Biopharma holds a strong position as a leading manufacturer of plasma protein and vaccine products globally. The company is a top performer in the influenza vaccine bidding market managed by PAHO and is actively expanding its presence in the U.S. market with Alyglo, aiming to capture a share of the significant immunoglobulin market.

The company faces industry-wide risks including policy changes, geopolitical tensions, and evolving regulatory landscapes, which can affect valuations. Intense competition, potential supply chain vulnerabilities, and the need to navigate complex drug pricing regulations in various European countries also present challenges.

GC Biopharma is focused on significant growth, projecting Alyglo sales of $100 million by the end of 2025 and $300 million by 2028 in the U.S. The company is also investing in an mRNA platform and developing innovative new drugs, aiming to advance vaccine technology and rare disease treatments.

Analysts anticipate GC Biopharma's operating profit to reach approximately W118.3 billion and EBITDA to be around W192.9 billion for the year 2025. This outlook is supported by its expanding global market presence and ongoing R&D investments.